Systemic Corticosteroids & Hormones

Prednisolone (Tablets IP 5mg/10mg/40mg) is an intermediate-acting synthetic glucocorticoid with four times the anti-inflammatory potency of hydrocortisone and minimal mineralocorticoid activity, on the WHO Model List of Essential Medicines. It diffuses across cell membranes and binds intracellular glucocorticoid receptors, inhibiting NF-kB, downregulating phospholipase A2, and potently suppressing synthesis of prostaglandins, leukotrienes, and pro-inflammatory cytokines. Indicated for severe autoimmune disorders (systemic lupus erythematosus, rheumatoid arthritis), acute asthma exacerbations, nephrotic syndrome, severe allergic reactions, inflammatory bowel disease, and immunosuppressive therapy.

Prednisolone (Tablets IP 5mg/10mg/40mg) is an intermediate-acting synthetic glucocorticoid with four times the anti-inflammatory potency of hydrocortisone and minimal mineralocorticoid activity, on the WHO Model List of Essential Medicines. It diffuses across cell membranes and binds intracellular glucocorticoid receptors, inhibiting NF-kB, downregulating phospholipase A2, and potently suppressing synthesis of prostaglandins, leukotrienes, and pro-inflammatory cytokines. Indicated for severe autoimmune disorders (systemic lupus erythematosus, rheumatoid arthritis), acute asthma exacerbations, nephrotic syndrome, severe allergic reactions, inflammatory bowel disease, and immunosuppressive therapy.

Dexamethasone (Tablets IP 0.5mg) is a long-acting synthetic fluorinated corticosteroid with 25 to 30 times the anti-inflammatory potency of hydrocortisone and virtually no mineralocorticoid (salt-retaining) activity, on the WHO Model List of Essential Medicines. It possesses exceptional tissue penetration including across the blood-brain barrier and placenta. Indicated for cerebral edema (brain tumors, trauma), severe COVID-19 with hypoxemia, croup, antenatal acceleration of fetal lung maturation in threatened preterm birth (24-34 weeks gestation), chemotherapy-induced nausea/vomiting, and severe allergic/anaphylactic crises.

Dexamethasone (Injection IP 4mg/ml) is a long-acting synthetic fluorinated corticosteroid with 25 to 30 times the anti-inflammatory potency of hydrocortisone and virtually no mineralocorticoid (salt-retaining) activity, on the WHO Model List of Essential Medicines. It possesses exceptional tissue penetration including across the blood-brain barrier and placenta. Indicated for cerebral edema (brain tumors, trauma), severe COVID-19 with hypoxemia, croup, antenatal acceleration of fetal lung maturation in threatened preterm birth (24-34 weeks gestation), chemotherapy-induced nausea/vomiting, and severe allergic/anaphylactic crises.

Betamethasone (Sodium Phosphate Tablets IP 0.5mg) is a potent, long-acting synthetic glucocorticoid on the WHO Model List of Essential Medicines. Structurally the 16-beta isomer of dexamethasone, it provides potent anti-inflammatory action with zero mineralocorticoid effect and readily crosses the placenta to stimulate fetal type II pneumocyte maturation and surfactant production. Indicated for antenatal prophylaxis of neonatal respiratory distress syndrome (RDS) and intraventricular hemorrhage in preterm labor, severe rheumatoid arthritis, angioedema, and dermatological autoimmune flares.

Prednisolone (Tablets IP 5mg/10mg/40mg) is an intermediate-acting synthetic glucocorticoid with four times the anti-inflammatory potency of hydrocortisone and minimal mineralocorticoid activity, on the WHO Model List of Essential Medicines. It diffuses across cell membranes and binds intracellular glucocorticoid receptors, inhibiting NF-kB, downregulating phospholipase A2, and potently suppressing synthesis of prostaglandins, leukotrienes, and pro-inflammatory cytokines. Indicated for severe autoimmune disorders (systemic lupus erythematosus, rheumatoid arthritis), acute asthma exacerbations, nephrotic syndrome, severe allergic reactions, inflammatory bowel disease, and immunosuppressive therapy.

Betamethasone (Injection IP 4mg/ml) is a potent, long-acting synthetic glucocorticoid on the WHO Model List of Essential Medicines. Structurally the 16-beta isomer of dexamethasone, it provides potent anti-inflammatory action with zero mineralocorticoid effect and readily crosses the placenta to stimulate fetal type II pneumocyte maturation and surfactant production. Indicated for antenatal prophylaxis of neonatal respiratory distress syndrome (RDS) and intraventricular hemorrhage in preterm labor, severe rheumatoid arthritis, angioedema, and dermatological autoimmune flares.

Hydrocortisone (Sodium Succinate Injection IP 100mg) is the bioidentical synthetic equivalent of endogenous human cortisol on the WHO Model List of Essential Medicines. It possesses balanced 1:1 glucocorticoid and mineralocorticoid activity, providing vital metabolic regulation, vascular tone maintenance, and immune stabilization. Indicated for acute adrenal crisis / Addisonian crisis (emergency IV therapy), chronic primary or secondary adrenocortical insufficiency (oral physiological replacement), congenital adrenal hyperplasia (CAH), severe septic shock unresponsive to vasopressors, and life-threatening anaphylaxis.

Triamcinolone (Acetonide Injection IP 40mg/ml) is an intermediate-acting synthetic fluorinated corticosteroid with 5 times the anti-inflammatory potency of hydrocortisone and no mineralocorticoid activity, on the WHO Model List of Essential Medicines. Formulated as a microcrystalline suspension for depot injection, it provides sustained local anti-inflammatory effect over 3 to 6 weeks. Indicated for intra-articular injection in severe osteoarthritis/rheumatoid arthritis, intralesional injection in keloids/alopecia areata, deep IM systemic therapy for chronic severe allergic conditions, and oral therapy for inflammatory disorders.

Triamcinolone (Tablets IP 4mg) is an intermediate-acting synthetic fluorinated corticosteroid with 5 times the anti-inflammatory potency of hydrocortisone and no mineralocorticoid activity, on the WHO Model List of Essential Medicines. Formulated as a microcrystalline suspension for depot injection, it provides sustained local anti-inflammatory effect over 3 to 6 weeks. Indicated for intra-articular injection in severe osteoarthritis/rheumatoid arthritis, intralesional injection in keloids/alopecia areata, deep IM systemic therapy for chronic severe allergic conditions, and oral therapy for inflammatory disorders.

Prednisolone (Tablets IP 5mg/10mg/40mg) is an intermediate-acting synthetic glucocorticoid with four times the anti-inflammatory potency of hydrocortisone and minimal mineralocorticoid activity, on the WHO Model List of Essential Medicines. It diffuses across cell membranes and binds intracellular glucocorticoid receptors, inhibiting NF-kB, downregulating phospholipase A2, and potently suppressing synthesis of prostaglandins, leukotrienes, and pro-inflammatory cytokines. Indicated for severe autoimmune disorders (systemic lupus erythematosus, rheumatoid arthritis), acute asthma exacerbations, nephrotic syndrome, severe allergic reactions, inflammatory bowel disease, and immunosuppressive therapy.

Prednisolone (Tablets IP 5mg/10mg/40mg) is an intermediate-acting synthetic glucocorticoid with four times the anti-inflammatory potency of hydrocortisone and minimal mineralocorticoid activity, on the WHO Model List of Essential Medicines. It diffuses across cell membranes and binds intracellular glucocorticoid receptors, inhibiting NF-kB, downregulating phospholipase A2, and potently suppressing synthesis of prostaglandins, leukotrienes, and pro-inflammatory cytokines. Indicated for severe autoimmune disorders (systemic lupus erythematosus, rheumatoid arthritis), acute asthma exacerbations, nephrotic syndrome, severe allergic reactions, inflammatory bowel disease, and immunosuppressive therapy.

Deflazacort Oral Suspension 6 mg per 5 ml is an oxazoline derivative of prednisolone with high glucocorticoid and minimal mineralocorticoid activity. In comparative clinical trials, it exhibits a more favorable metabolic and bone safety profile, causing significantly less calcium loss, bone demineralization, growth retardation, and carbohydrate intolerance than conventional prednisone or prednisolone. Indicated for Duchenne muscular dystrophy (DMD) in pediatric patients (age >=2 years), juvenile idiopathic arthritis, severe pediatric asthma, nephrotic syndrome, and chronic autoimmune disorders.

Hydrocortisone (Tablets 5mg/10mg) is the bioidentical synthetic equivalent of endogenous human cortisol on the WHO Model List of Essential Medicines. It possesses balanced 1:1 glucocorticoid and mineralocorticoid activity, providing vital metabolic regulation, vascular tone maintenance, and immune stabilization. Indicated for acute adrenal crisis / Addisonian crisis (emergency IV therapy), chronic primary or secondary adrenocortical insufficiency (oral physiological replacement), congenital adrenal hyperplasia (CAH), severe septic shock unresponsive to vasopressors, and life-threatening anaphylaxis.

Hydrocortisone (Tablets 5mg/10mg) is the bioidentical synthetic equivalent of endogenous human cortisol on the WHO Model List of Essential Medicines. It possesses balanced 1:1 glucocorticoid and mineralocorticoid activity, providing vital metabolic regulation, vascular tone maintenance, and immune stabilization. Indicated for acute adrenal crisis / Addisonian crisis (emergency IV therapy), chronic primary or secondary adrenocortical insufficiency (oral physiological replacement), congenital adrenal hyperplasia (CAH), severe septic shock unresponsive to vasopressors, and life-threatening anaphylaxis.

Prednisolone (Syrup 15mg/5ml) is an intermediate-acting synthetic glucocorticoid with four times the anti-inflammatory potency of hydrocortisone and minimal mineralocorticoid activity, on the WHO Model List of Essential Medicines. It diffuses across cell membranes and binds intracellular glucocorticoid receptors, inhibiting NF-kB, downregulating phospholipase A2, and potently suppressing synthesis of prostaglandins, leukotrienes, and pro-inflammatory cytokines. Indicated for severe autoimmune disorders (systemic lupus erythematosus, rheumatoid arthritis), acute asthma exacerbations, nephrotic syndrome, severe allergic reactions, inflammatory bowel disease, and immunosuppressive therapy.

Prednisolone (Dispersible Tablets 20mg) is an intermediate-acting synthetic glucocorticoid with four times the anti-inflammatory potency of hydrocortisone and minimal mineralocorticoid activity, on the WHO Model List of Essential Medicines. It diffuses across cell membranes and binds intracellular glucocorticoid receptors, inhibiting NF-kB, downregulating phospholipase A2, and potently suppressing synthesis of prostaglandins, leukotrienes, and pro-inflammatory cytokines. Indicated for severe autoimmune disorders (systemic lupus erythematosus, rheumatoid arthritis), acute asthma exacerbations, nephrotic syndrome, severe allergic reactions, inflammatory bowel disease, and immunosuppressive therapy.

Prednisolone (Tablets IP 5mg/10mg/40mg) is an intermediate-acting synthetic glucocorticoid with four times the anti-inflammatory potency of hydrocortisone and minimal mineralocorticoid activity, on the WHO Model List of Essential Medicines. It diffuses across cell membranes and binds intracellular glucocorticoid receptors, inhibiting NF-kB, downregulating phospholipase A2, and potently suppressing synthesis of prostaglandins, leukotrienes, and pro-inflammatory cytokines. Indicated for severe autoimmune disorders (systemic lupus erythematosus, rheumatoid arthritis), acute asthma exacerbations, nephrotic syndrome, severe allergic reactions, inflammatory bowel disease, and immunosuppressive therapy.